Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, randomised, parallel group, multicentre study to compare the efficacy and safety of Flutiform pMDI vs Fluticasone pMDI Plus Formoterol DPI in adolescent and adult subjects with mild to moderate-severe persistent, reversible asthma

Trial Profile

An open, randomised, parallel group, multicentre study to compare the efficacy and safety of Flutiform pMDI vs Fluticasone pMDI Plus Formoterol DPI in adolescent and adult subjects with mild to moderate-severe persistent, reversible asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 07 Aug 2012 Additional location (Belgium) added as reported by European Clinical Trials Database.
    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
    • 22 Jul 2008 The primary endpoint has been met, according to a SkyePharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top